
Rosemont Pharmaceuticals agreed to acquire Aytu BioPharma in an all-cash tender offer at $2.70 per share, a 41.1% premium to Aytu’s 30-day volume-weighted average price and 51.7% above Friday’s close, valuing the deal at about $56 million. Aytu’s board unanimously approved the agreement, with closing expected in late December 2026. The deal gives Rosemont Aytu’s ADHD portfolio and an emerging depression asset alongside a U.S. commercial platform.